Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$23.7 million.

  • Abeona Therapeutics' Free Cash Flow fell 8758.51% to -$23.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 6286.98%. This contributed to the annual value of -$58.5 million for FY2024, which is 5656.4% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Free Cash Flow is -$23.7 million, which was down 8758.51% from -$21.7 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Free Cash Flow peaked at -$5.8 million during Q3 2023, and registered a low of -$33.5 million during Q4 2021.
  • Its 5-year average for Free Cash Flow is -$14.4 million, with a median of -$13.4 million in 2024.
  • In the last 5 years, Abeona Therapeutics' Free Cash Flow plummeted by 193925.75% in 2021 and then surged by 5816.45% in 2022.
  • Abeona Therapeutics' Free Cash Flow (Quarter) stood at -$33.5 million in 2021, then skyrocketed by 58.16% to -$14.0 million in 2022, then soared by 33.85% to -$9.3 million in 2023, then tumbled by 85.13% to -$17.2 million in 2024, then tumbled by 38.11% to -$23.7 million in 2025.
  • Its Free Cash Flow stands at -$23.7 million for Q3 2025, versus -$21.7 million for Q2 2025 and -$19.8 million for Q1 2025.